Onkologie 2020: 14(Suppl.E): 131-134 | DOI: 10.36290/xon.2020.072

Good results of pembrolizumab treatment in a patient with double lung cancer

Jana Krejčí

Pneumologická klinika Nemocnice na Bulovce, Praha

Immunotherapy is a new and currently the most promising treatment strategy in oncology. It can significantly prolong the life of patients with bronchogenic carcinoma without impairing their quality of life. That has to do with the fact that adverse effects, in comparison with standard chemotherapy, are significantly lower and of a different spectrum. Among the drugs used is pembrolizumab which, in the Czech Republic, is indicated and reimbursed in patients with metastatic non-small cell lung cancer (NSCLC) in the first line of treatment. To meet the reimbursement requirements, the patient must be in a good general condition (ECOG PS 0-1), tumour cells must express PD-L1 in more than 50 % and must not exhibit EGFR or ALK positivity. Our case report aims to document not only an excellent treatment response to pembrolizumab in the first line, but also a preservation of the quality of life.

Keywords: NSCLC, immunotherapy, pembrolizumab, PD-L1.

Published: September 25, 2020  Show citation